Abstracts tagged "Cancer"

Abstract Number: 849 • 2017 ACR/ARHP Annual Meeting
Tumor TIF1 Mutations and Loss of Heterozygosity Related to Cancer Associated Myositis
Iago Pinal-Fernandez¹, Berta Ferrer-Fabregas², Ernesto Trallero-Araguas¹, Eva Balada¹, Maria Angeles Martinez³, Jose Cesar Milisenda⁴, Gloria Aparicio-Español⁵, Moises Labrador-Horrillo¹, Vicente Garcia-Patos¹, Josep Maria Grau-Junyent⁴ and Albert Selva O'Callaghan⁶, ¹Internal Medicine, Autoimmune Diseases Unit. Vall d´Hebron Hospital, Barcelona, Spain, ²Pathology, Vall d´Hebron, Barcelona, Spain, ³Immunology, Immunology Department, Barcelona, Spain, ⁴Muscle Research Group and Ciberer, Hospital Clinic Provincial, Barcelona, Spain, ⁵Dermatology, Vall d´Hebron Hospital, Barcelona, Spain, ⁶Internal Medicine, Hospital Universitari General Vall d'Hebron, Barcelona, Spain
Background/Purpose: To analyze the influence of genetic alterations and differential expression of the TIF1 genes in the pathophysiology of cancer-associated myositis (CAM). Methods: Whole exome…
Abstract Number: 853 • 2017 ACR/ARHP Annual Meeting
Anti-TIF-1 Antibody Positivity Is Associated with a Five-Fold Increase in Cancer Risk in the Idiopathic Inflammatory Myopathies
Alexander Oldroyd^1,2, Jamie C Sergeant^1,3, Paul New⁴, Neil J. McHugh^5,6, Zoe Betteridge⁵, Janine Lamb⁷, William Ollier⁷, Robert Cooper^4,7,8 and Hector Chinoy^2,9, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester, United Kingdom, ³Centre for Biostatistics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴MRC/ARUK Centre for Integrated Research into Musculoskeletal Ageing, University of Liverpool, Liverpool, United Kingdom, ⁵Department of Pharmacy and Pharmacology, The University of Bath, Bath, United Kingdom, ⁶Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom, ⁷Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁸Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ⁹Department of Rheumatology, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, United Kingdom
Background/Purpose: There is an increased cancer risk associated with the idiopathic inflammatory myopathies (IIM). Studies have identified that positivity for the autoantibody against transcriptional intermediary…
Abstract Number: 1146 • 2017 ACR/ARHP Annual Meeting
Associations between Gout and Cancer in an Nhanes Cohort
Patricia Kachur¹, Venkatesh Gondhi², Yinjin Wert³ and Pramil Cheriyath², ¹Internal Medicine, Ocala Regional Medical Center, Ocala, FL, ²Ocala Regional Medical Center, Ocala, FL, ³Pinnacle Health System, Harrisburg, PA
Background/Purpose: Gout is the most common inflammatory disease in the United States (US), affecting more than 4% of the population. Although uric acid (UA) can…
Abstract Number: 26 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Factor Positivity Increases All-Cause and Cancer Mortality Risk in Korean Healthy Examinees: A Kangbuk Samsung Health Study
Joong Kyong Ahn¹, Jiwon Hwang², Hyemin Jeong³, Ji Young Chae⁴, Hyungjin Kim³, Hoon-Suk Cha³ and Eun-Mi Koh³, ¹Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, National Police Hospital, Seoul, Korea, The Republic of, ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Departement of Internal Medicine, Bundang Jesaeng General Hospital, Seongnam, Korea, The Republic of
Background/Purpose: Several studies have reported increased overall mortality in association with rheumatoid factor (RF) in RA. However, the clinical significance including health outcomes of RF…
Abstract Number: 330 • 2016 ACR/ARHP Annual Meeting
Safety of Denosumab in Postmenopausal Osteoporosis and in Cancer and Bone Metastase Treatment: A Systematic Review and Meta-Analysis
Marlène Aubailly¹, Bernard Combe², Cécile Gaujoux-Viala³, Cédric Lukas⁴, Jacques Morel⁵ and Hélène Che¹, ¹rheumatology, CHU Lapeyronie, University of Montpellier, France, ²Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ³CHU Nîmes, University of Montpellier, France, ⁴Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁵Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France
Background/Purpose: Denosumab is a RANK ligand antibody and the first biologic agent used for the treatment of post-menopausal osteoporosis (OP) and prevention of bone metastases…
Abstract Number: 855 • 2016 ACR/ARHP Annual Meeting
The Relationship Between Systemic Sclerosis and Breast Cancer and the Effects on Treatment Outcome
Pichaya O-charoen¹, Katherine Glass², William Messner³ and Soumya Chatterjee⁴, ¹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, ³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ⁴Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH
Background/Purpose: Breast cancer has been shown to be more prevalent in patients with systemic sclerosis (SSc) compared to that in the general population. A close…
Abstract Number: 2000 • 2016 ACR/ARHP Annual Meeting
Incidence of Cancer in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept
Jacques-Eric Gottenberg¹, Philippe Ravaud², Thomas Bardin³, Alain Cantagrel⁴, Bernard Combe⁵, Maxime Dougados⁶, RENE MARC FLIPO⁷, Olivier Vittecoq⁸, Thierry Schaeverbeke⁹, Isabelle Pane¹⁰, Jean Sibilia¹¹, Xavier Mariette¹² and on behaf of all of the investigators of the AIR registry and of the French Society of Rheumatology , ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hotel Dieu, PARIS, France, ³Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁴Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, ⁵Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁶Rheumatology, Paris Descartes University, Paris, France, ⁷Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, ⁸INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ⁹Rheumatology, CHU Bordeaux, Bordeaux, France, ¹⁰Epidemiology, Hotel Dieu, Paris, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Institut National de la Santé et de la Recherche Médicale, Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: Patients with a history of cancer were excluded from pivotal clinical trials evaluating biologics. Therefore, only registries can inform us on the incidence of…
Abstract Number: 2304 • 2016 ACR/ARHP Annual Meeting
Decreased Occurrence of Colon Cancer Among Gout Patients: Assessment By Physician Diagnosis and Colonoscopy
Anastasia Slobodnick^1,2, Svetlana Krasnokutsky Samuels³, Aaron Lehmann⁴, Robert Keenan⁵, Fritz Francois⁶ and Michael H. Pillinger^3,7, ¹Medicine/Rheumatology, NYU School of Medicine, New York, NY, ²Medicine/Rheumatology, VA New York Harbor Health Care System, NY Campus, New York, NY, ³VA New York Harbor Health Care System, New York, NY, ⁴Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ⁵Division of Rheumatology, Duke University, Durham, NC, ⁶Medicine/Gastroenterology, NYU School of Medicine, New York, NY, ⁷NYU School of Medicine, New York, NY
Background/Purpose: The relationship between gout and cancer remains unclear. Whereas some studies have reported possible anti-cancer benefits of uric acid and monosodium urate crystals, others…
Abstract Number: 2314 • 2016 ACR/ARHP Annual Meeting
Anti-Mi2 Dermatomyositis Revisited: Pure DM Phenotype with Muscle Fiber Necrosis and High Risk of Malignancy
Océane Landon-Cardinal¹, Grégoire Monseau², Yoland Schoindre³, Aude Rigolet¹, Nicolas Champtiaux¹, Baptiste Hervier¹, Agathe Masseau⁴, Eric Hachulla⁵, Thomas Papo⁶, Benjamin Terrier⁷, Alain Meyer⁸, Jean-Emmanuel Kahn³, François Maurier⁹, Francis Gaches¹⁰, Emmanuelle Salort-Campana¹¹, Thierry Zenone¹², Nathalie Costedoat-Chalumeau⁷, Florian Perez¹³, Maxime Samson¹⁴, Anne-Marie Piette³, Guillaume Moulis¹⁰, Sylvain Audia¹⁵, Séverine Genot¹⁶, Nicolas Schleinitz¹⁷, Guillaume Lefevre⁵, Laurence Verneuil¹⁸, Olivier Benveniste¹⁹, Yves Allenbach¹ and Boris Bienvenu²⁰, ¹Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ²Internal Medicine, Caen University Hospital, Caen, France, ³Internal Medicine, Foch Hospital, Suresnes, France, ⁴Internal Medicine, Nantes University Hospital, Nantes, France, ⁵Internal Medicine, Lille University Hospital, Lille, France, ⁶Bichat University Hospital - Internal Medicine, Paris, France, ⁷Internal Medicine, Cochin University Hospital, Paris, France, ⁸Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹Internal Medicine, Sainte-Blandine de Metz Hospital, Metz, France, ¹⁰Internal Medicine, Toulouse University Hospital, Toulouse, France, ¹¹Neurology, La Timone University Hospital, Marseille, France, ¹²Internal Medicine, Valence Hospital, Valence, France, ¹³Neurology, Albi Hospital, Albi, France, ¹⁴Dijon University Hospital, Dijon, France, ¹⁵Internal Medicine, Dijon University Hospital, Dijon, France, ¹⁶Internal Medicine, Martigues Hospital, Martigues, France, ¹⁷La Timone University Hospital, Marseille, France, ¹⁸Dermatology, Caen University Hospital, Caen, France, ¹⁹Pitié-Salpêtrière University Hospital, Paris, France, ²⁰Caen University Hospital, Caen, France
Background/Purpose: Anti-Mi2 autoantibodies (Aabs) have been proposed to be highly specific for dermatomyositis (DM) and to be associated with a DM classical phenotype consisting of…
Abstract Number: 2320 • 2016 ACR/ARHP Annual Meeting
Oropharyngeal Dysphagia in Autoimmune Myositis
Jessica Nehme¹, Jean-Paul Makhzoum², Josiane Bourré-Tessier³, Yves Troyanov⁴, Marianne Landry¹, Océane Landon-Cardinal⁵, Marvin J. Fritzler⁶, Anne-Marie Mansour⁷, Eric Rich⁸, Jean-Richard Goulet⁹, Tamara Grodzicky¹⁰, Edith Villeneuve², Frédéric Massicotte¹¹, Florence Weber¹², Martial Koenig¹³, Sylvie Desmarais¹⁴, José Ferreira², Benjamin Ellezam¹⁵, Ira N. Targoff¹⁶ and Jean-Luc Senécal², ¹Université de Montréal, Montreal, QC, Canada, ²Université de Montréal, Montréal, QC, Canada, ³Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴Rheumatology, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ⁵Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁶Medicine, University of Calgary, Calgary, AB, Canada, ⁷medicine, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ⁸Div of Rheumatology, C H Univ de Montreal, Montreal, QC, Canada, ⁹246 av Edison, CHUM - H, Saint-Lambert, QC, Canada, ¹⁰Rheumatology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ¹¹Hôpital Notre-Dame, Montr, QC, Canada, ¹²Hôpital St-Luc, Montreal, QC, Canada, ¹³Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ¹⁴Centre Hospitalier Pierre-Boucher, Longueuil, QC, Canada, ¹⁵Hôpital Ste-Justine, Montreal, QC, Canada, ¹⁶University of Oklahoma, Oklahoma City, OK
Background/Purpose: Oropharyngeal dysphagia (OPD) is an ominous finding in autoimmune myositis (AIM), yet few studies have evaluated the disease subsets at higher risk for this…
Abstract Number: 2447 • 2016 ACR/ARHP Annual Meeting
Does a History of Abnormal Pap Smear or Preceeding HPV Infection Affect Humoral Immune Response to Quadrivalent Human Papilloma Virus (qHPV) Vaccine in Women with Systemic Lupus Erythematosus (SLE)
J. Patricia Dhar^1,2, Lynnette Essenmacher³, Renee Dhar⁴, Ardella Magee⁵, Joel Ager⁶ and Robert Sokol⁷, ¹Internal Medicine, Wayne State University School of Medicine, Detroit, MI, ²Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI, ³Wayne State University School of Medicine, Detroit, MI, ⁴CMED medical student, Central Michigan University College of Medicine, Mt. Pleasant, MI, ⁵Clinical and Translational Research Center, Wayne State University, Detroit, MI, ⁶Family Medicine, Wayne State University School of Medicine, Detroit, MI, ⁷Department of Obstetrics & Gynecology, Wayne State University School of Medicine, Detroit, MI
Background/Purpose: Cervical neoplasia is increased in women with SLE. HPV types 16 & 18 account for 70% of cervical cancer. Natural HPV cervical infection generates…
Abstract Number: 2629 • 2016 ACR/ARHP Annual Meeting
Serious Adverse Events in Patients with RA Taking Abatacept Compared with Other Dmards. Results from a US-Wide Safety Registry
Kaleb Michaud^1,2, Sofia Pedro², TA Simon³, Frederick Wolfe² and Rebecca Schumacher², ¹University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Observational studies are critical in assessing medication safety and effectiveness in the real world. Nonrandom assignment can provide insight to how and when medications…
Abstract Number: 2990 • 2016 ACR/ARHP Annual Meeting
Cancer in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort
Sasha Bernatsky¹, Murray Urowitz², John Hanly³, Ann E. Clarke⁴, Caroline Gordon⁵, Juanita Romero-Diaz⁶, Graciela S. Alarcon⁷, Sang-Cheol Bae⁸, Michelle Petri⁹, Joan T. Merrill¹⁰, Daniel J Wallace¹¹, Paul R. Fortin¹², Dafna D. Gladman¹³, David A. Isenberg¹⁴, Anisur Rahman¹⁵, Susan Manzi¹⁶, Ola Nived¹⁷, Gunnar K. Sturfelt¹⁸, Christine Peschken¹⁹, Jorge Sánchez-Guerrero²⁰, Guillermo Ruiz-Irastorza²¹, Cynthia Aranow²², Ronald F. van Vollenhoven²³, Asad Zoma²⁴, Kristján Steinsson²⁵, M Khamashta²⁶, Ellen M. Ginzler²⁷, Anca Askanase²⁸, Kenneth C. Kalunian²⁹, Mary Anne Dooley³⁰, S. Sam Lim³¹, Diane L. Kamen³², Søren Jacobsen³³, Manuel Ramos-Casals³⁴, Murat Inanc³⁵, Jeremy Labrecque³⁶, Jennifer LF Lee³⁷ and Rosalind Ramsey-Goldman³⁸, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁷Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of, ⁹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹²Université Laval, CHU de Québec, Québec, QC, Canada, ¹³Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹⁵Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁶Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁷Department of Rheumatology, University Hospital, Lund, Sweden, ¹⁸Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ¹⁹Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ²⁰Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, ²¹Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, ²²Feinstein Institute for Medical Research, Manhasset, NY, ²³Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ²⁴Hairmyres Hospital, Scotland, United Kingdom, ²⁵Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁶Lupus Research Unit, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ²⁷Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ²⁸NYU, Seligman Centre for Advanced Therapeutics, New York, NY, ²⁹Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³⁰Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ³¹Medicine, Emory University School of Medicine, Atlanta, GA, ³²Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³³Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ³⁵Internal Medicine, Istanbul University, Istanbul, Turkey, ³⁶Clinical Epidemiology, McGill UHC/RVH, Montreal, QC, Canada, ³⁷Clinical Epidemiology Rheum, McGill UHC/RVH, Montreal, QC, Canada, ³⁸FSM, Northwestern University, Chicago, IL
Background/Purpose: Published studies of cancer risk in SLE to date have never focussed solely on clinically confirmed, incident patients. Prior studies thus may not reflect the cancer…
Abstract Number: 3067 • 2016 ACR/ARHP Annual Meeting
Treatment Decisions Following Diagnosis of Cancer during TNFi Inhibitor Treatment in Patients with Rheumatoid Arthritis: Results from the BSRBR-RA
Katie Druce¹, Diederik Decock², Kath Watson¹, Deborah P.M. Symmons¹ and Kimme L. Hyrich¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Treatment Decisions Following Diagnosis of Cancer During TNFi inhibitor Treatment in Patients with Rheumatoid Arthritis: results from the BSRBR-RA Druce KL, De Cock D, Watson…
Abstract Number: 3080 • 2016 ACR/ARHP Annual Meeting
Rheumatologic Consequences of Immunotherapy to Treat Malignancies: The Tip of an Iceberg
Laura Cappelli¹, Anna Kristina Gutierrez², Alan N. Baer², Jemima Albayda³, Rebecca L. Manno², Uzma Haque³, Ami A. Shah³, Evan Lipson⁴, Karen Bleich⁵, Julie Brahmer⁴, Patrick Forde⁴, Dung Le⁶, Jarushka Naidoo⁴ and Clifton Bingham III⁷, ¹Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Johns Hopkins University, Baltimore, MD
Rheumatologic Consequences of Immunotherapy to Treat Malignancies: The Tip of an Iceberg Background/Purpose: Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].